Department of Urology, Children's Hospital of Chongqing Medical University, Chongqing, P.R. China.
Chongqing Key Laboratory of Children Urogenital Development and Tissue Engineering, Children's Hospital of Chongqing Medical University, Chongqing, P.R. China.
Drug Deliv. 2022 Dec;29(1):3291-3303. doi: 10.1080/10717544.2022.2141921.
Osteosarcoma is a bone tumor with a high incidence in children and adolescents. Chemotherapy for osteosarcoma is limited, and effective targeted drugs are urgently needed to treat osteosarcoma. Exosomes as a natural nano drug delivery platform have been widely studied and proven to have good drug delivery performance. However, the low production of exosomes hinders its development as a carrier. Exosome mimetics (EMs) as an alternative product of exosomes solve the problem of low production of exosomes and maintain the good performance of exosomes as carriers. In this study, bone marrow mesenchymal stem cells (BMSCs) were sequentially extruded to generate EMs to encapsulate doxorubicin (EM-Dox) to treat osteosarcoma. The results showed that we successfully prepared EMs of BMSC, and EM-Dox was prepared using an active-loading approach. Our engineered EM-Dox demonstrated significantly more potent tumor inhibition activity and fewer side effects than free doxorubicin. This novel biological nanomedicine system provides a promising opportunity to develop novel precision medicine for osteosarcoma.
骨肉瘤是一种儿童和青少年高发的骨肿瘤。骨肉瘤的化疗效果有限，急需有效的靶向药物来治疗骨肉瘤。外泌体作为一种天然的纳米药物递送平台，已得到广泛研究，并被证明具有良好的药物递送性能。然而，外泌体的产量低阻碍了其作为载体的发展。外泌体模拟物（EMs）作为外泌体的替代产物，解决了外泌体产量低的问题，同时保持了外泌体作为载体的良好性能。在这项研究中，骨髓间充质干细胞（BMSCs）被连续挤出以产生包载多柔比星（EM-Dox）的 EMs 来治疗骨肉瘤。结果表明，我们成功制备了 BMSC 的 EMs，并采用主动载药的方法制备了 EM-Dox。我们设计的 EM-Dox 比游离多柔比星具有更强的肿瘤抑制活性和更少的副作用。这种新型生物纳米医学系统为开发治疗骨肉瘤的新型精准医学提供了有前途的机会。
